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Abnormalities in brain development, thought to be irreversible in adults, have long been assumed to underlie
the neurological and psychiatric symptoms associated with neurodevelopmental disorders. Surprisingly,
a number of recent animal model studies of neurodevelopmental disorders demonstrate that reversing the
underlyingmolecular deficits can result in substantial improvements in function even if treatments are started
in adulthood. These findings mark a paradigmatic change in the way we understand and envision treating
neurodevelopmental disorders.The term ‘‘neurodevelopmental disorders’’ encompasses a large
group of disorders that share the fact that disease onset is during
periods of ongoing maturation and development. These disor-
ders are often associated with complex neuropsychiatric
features including intellectual disability, specific learning disabil-
ities, ADHD, autism, and epilepsy, among others. Neurodevelop-
mental disorders are caused by a wide range of genetic muta-
tions and environmental factors (e.g., infections, immune
dysfunction, intoxication, endocrine and metabolic dysfunction,
nutritional factors, trauma, etc.). Heritability estimates indicate
that genetic factors play an important role in these disorders.
Although our review is focused on single-gene disorders, the
basic implications discussed may be more broadly relevant
and therefore applicable to neurodevelopmental disorders in
general.
The Traditional View
Neurodevelopmental disorders are thought to be caused by
changes in development, potentially involving alterations in
neurogenesis, cell migration, and neuronal connectivity that are
responsible for cognitive deficits in adults. Accordingly, abnor-
malities in brain structure, resulting from perturbed development,
are often associated with neurodevelopmental disorders. Addi-
tionally, development is an especially vulnerable period: insults
with a minor impact in adults can result in significant pathologies
when occurring during development. For example, absence of
serotonin1A receptor function in the forebrain during postnatal
development, but not in adulthood, results in anxiety-related
behavioral phenotypes in mice (Gross et al., 2002). Similarly,
maternal care during early postnatal periods has been shown to
influence hippocampal glucocorticoid receptor expression,
stress responsiveness, and behavior in the offspring via epige-
netic modulations that last into adulthood (Caldji et al., 1998;
Francis et al., 1999; Liu et al., 1997; Weaver et al., 2004). A recent
study with an animal model of schizophrenia (Li et al., 2007)
showed that a brief induction of a DISC1 mutant allele during
postnatal development, but not in adults, is sufficient to trigger
many of the phenotypes associated with this neurodevelopmen-950 Neuron 60, December 26, 2008 ª2008 Elsevier Inc.tal disorder (Weinberger, 1987). Clinical experience with endo-
crine and metabolic disorders also stresses the importance of
insults during vulnerable periods of development: hypothy-
roidism and phenylketonuria, for example, can lead to profound
and irreversible cognitive disability when left uncorrected during
developmental periods, while they appear to have milder effects
in adults (Davis and Tremont, 2007; Dugbartey, 1998; Hanley,
2004; Rovet and Daneman, 2003; Zoeller and Rovet, 2004).
Nevertheless, there are many other examples of pathologies
where the opposite is true: for example, trauma, infection, and
ischemia may have much of the same or even more dire effects
in adults than in developing organisms (Kolb et al., 2000;
Vannucci and Hagberg, 2004).
Many of the mutations that cause developmental disorders
disrupt gene(s) that are also expressed in the adult brain. Thus,
in addition to developmental effects on brain structure and func-
tion, it is possible that altered gene function in adulthood may
contribute to associated cognitive phenotypes. Accordingly,
a number of recent studies of animal models of neurodevelop-
mental disorders strongly suggest that adult disruption of gene
function makes a significant contribution to cognitive disability
and neurological dysfunction associated with these disorders.
These studies demonstrate that treating the disrupted molecular
and cellular mechanisms specifically in adults can result in
dramatic improvements in cognitive function. It is conceivable
that biochemical amelioration of the underlying genetic deficits
may allow robust molecular, cellular, structural, and behavioral
plasticity mechanisms in the adult brain to compensate for or
even correct specific developmental pathologies.
Adult Recovery of Cognition in Animal Models
of Neurodevelopmental Disorders
Recent studies using animal models of several single-gene devel-
opmental disorders provide compelling evidence that cognitive
deficits and neurological impairments associated with neurode-
velopmental disorders can be reversed, even if treatment is initi-
ated in adults (Table 1). For example, neurofibromatosis I (NF1) is
a complex developmental genetic disorder caused by mutations
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ties with visuospatial skills, memory, and attentional-executive
function, are commonly associated with NF1. Mice with a hetero-
zygous deletion of the Nf1 gene (Nf1+/ mice) displayed spatial
learning deficits (Silva et al., 1997) and impairments in atten-
tional-executive function (Li et al., 2005), akin to neuropsycholog-
ical impairments observed in NF1 patients. The NF1 gene
encodes neurofibromin, a GTPase-activating protein that accel-
erates the inactivation of Ras, thereby inhibiting Ras-MAPK
signaling. Accordingly, loss-of-function mutations in the NF1
gene lead to disinhibited Ras-MAPK signaling, a pathway with
a known role in neurodevelopment. Nf1+/ mice show defects
in long-term potentiation (LTP) due to increased inhibitory
neurotransmission in the hippocampus (Costa et al., 2002).
Two pharmacological strategies that reduce the isoprenylation
of Ras, and thereby decrease active (membrane-bound) Ras,
have been used to rescue the signaling, physiology, and behav-
ioral deficits of these mice: farnesyl-transferase inhibition with
BMS 191563 (Costa et al., 2002) and HMG-CoA reductase inhibi-
tion with lovastatin (Li et al., 2005). HMG-CoA reductase is the
rate-limiting enzyme in the mevalonate pathway in which
isoprenyl groups (and then cholesterol) are synthesized. Notably,
a short pharmacological treatment of adult mice was sufficient to
decrease Ras-MAPK signaling, restore LTP, and reverse cogni-
tive deficits in Nf1+/ mice. Drug doses sufficient to rescue the
phenotypes of the mutants did not have a measurable effect on
controls (Costa et al., 2002; Li et al., 2005), a result that indicates
that the drugs used targeted the mechanisms disrupted in these
mutants. Importantly, a recent clinical study reported that
although a brief 12 week simvastatin treatment did not have a
significant overall effect on the cognition of patients, it did rescue
deficits in an object assembly test (Krab et al., 2008). Moreover,
the treatment had the biggest impact on patients with the poorest
performances, while not affecting the performances of patients
with scores within the normal range. Although promising, longer
treatments with larger sample sizes are needed to confirm that
statins have a beneficial impact on the cognition of NF1 patients.
Remarkably, similar to the Nf1+/ mice (Costa et al., 2002), the
hippocampal learning and memory deficits of an animal model of
Down’s syndrome (the Ts65Dn mice) appear to be due to deficits
in hippocampal LTP caused by enhanced GABAergic inhibition
(Kleschevnikov et al., 2004). Down’s syndrome, caused by
trisomy 21, is the most common genetic disorder associated
with intellectual disability. The Ts65Dn mouse model of the
disorder (Reeves et al., 1995) is based on the partial triplication
of chromosome 16, the mouse homolog to human chromosome
21. Until recently, nearly all of the mechanistic studies of this
disorder focused on the impact of genetic changes on develop-
ment. A recent ground-breaking study, aimed at testing the
hypothesis that abnormally high levels of inhibition in adult mice
play a role in the pathogenesis of Down’s syndrome-related
cognitive dysfunction (Fernandez et al., 2007), showed that
although acute treatment (1 day) with a GABAA receptor antago-
nist (picrotoxin) had no effect, a 2 week treatment with several
GABAA receptor antagonists (picrotoxin, pentylenetetrazole, or
bilobalide) rescued cognitive deficits (object recognition, sponta-
neous alternation) in adult Ts65Dn mice. The same treatment did
not affect learning in controls, a result consistent with the ideathat increased inhibition accounts for the learning and memory
deficits in Ts65Dn mice.
Surprisingly, an 2 week treatment with GABAA antagonists
(Fernandez et al., 2007) led to a persistent (for at least up to
2 months) behavioral recovery even though the treatment was
not extended beyond the initial 2 week period. Similarly, this
treatment also resulted in the (partial) rescue of LTP, even when
LTP was tested 3 months after the completion of the 2 week
treatment. These findings have been recently confirmed and
extended in a study that showed that a 7 week treatment with
the GABAA receptor antagonist pentylenetetrazole also rescues
spatial learning deficits in adult Ts65Dn mice (Rueda et al.,
2008). The results reviewed above show that reversing the
increased inhibition in the Ts65Dn mutants triggered lasting
adaptive changes that result in improvements in cognition. The
unexpected (and unexplained) delayed therapeutic action of
this treatment is reminiscent of other psychopharmacological
effects, such as the well-known delayed effect of antidepres-
sants. Could treatment with GABA receptor inhibitors, and the
resulting lowering of inhibitory tone, lead to the reactivation of
developmental plasticity processes (see discussion below) that
contributed to the restored LTP and learning of the Ts65Dn
mice? Could similar treatments reverse the cognitive deficits
associated with Down’s syndrome?
Rubinstein-Taybi syndrome (RTS) is another genetic disorder
characterized by intellectual disability and characteristic physical
features that include broad thumbs and toes as well as facial
abnormalities (Rubinstein and Taybi, 1963). Although there are
multiple genes implicated in RTS, mutations in the CREB-binding
protein (CBP) are known to cause this syndrome (Petrij et al.,
1995). CBP is a transcriptional coactivator, has histone acetyl-
transferase activity, and is involved in transcriptional control
downstream of cAMP signaling, linking experience-dependent
neuronal activation to gene expression and long-term memory
formation (Hallam and Bourtchouladze, 2006; Lonze and Ginty,
2002). A mouse model of RTS (Cbp+/ mice) shows normal
short-term memory but impaired long-term memory in context
fear conditioning and object recognition (Alarcon et al., 2004;
Bourtchouladze et al., 2003). Memory deficits in Cbp+/ mice
could be restored in adult mice using pharmacological strategies
that enhance CREB-dependent gene expression: the HDAC
inhibitor SAHA is known to promote histone acetylation, and it
was shown to improve context fear memory in Cbp+/ mice
(Alarcon et al., 2004). Second, phospodiesterase-4 (PDE-4)
inhibitors (inhibit breakdown of cAMP) also improve long-term
memory in adult Cbp+/ mice (Bourtchouladze et al., 2003),
perhaps because they enhance PKA-dependent CREB activa-
tion. HDAC inhibitors and PDE-4 antagonists therefore hold
therapeutic promise for cognitive deficits associated with RTS.
However, it is important to note that these drugs also improved
long-term memory in wild-type mice. Importantly, these studies
in Cbp+/ mice illustrate the potential power of targeting tran-
scriptional regulatory processes to induce lasting therapeutic
changes in the adult brain. In line with this, the work from Meaney
and colleagues mentioned above also showed that transcrip-
tional derepression (with the HDAC inhibitor trichostatin A) in
adult animals reverses functional consequences (increased
stress responsiveness) of early life experiences (maternal careNeuron 60, December 26, 2008 ª2008 Elsevier Inc. 951
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Reviewbehavior) that are mediated by epigenetic alterations (methyla-
tion within the glucocorticoid receptor promoter) (Weaver et al.,
2004).
Tuberous sclerosis complex (TSC) is a single-gene disorder
associated with intellectual disability and autism and involves
signaling changes that affect translational control; TSC is caused
by heterozygous mutations in either the TSC1 or the TSC2 gene
(Consortium, 1993; van Slegtenhorst et al., 1997), and besides
intellectual disability and autism, affected subjects frequently
exhibit epilepsy, ADHD, and specific learning disabilities (de
Vries et al., 2005; Joinson et al., 2003). Developmental brain
abnormalities (cortical tubers) and early-onset seizures (infantile
spasms) have long been proposed to cause the cognitive
disability associated with TSC (O’Callaghan et al., 2004; Razna-
han et al., 2007). Tubers and infantile spasms, however, only
partially account for the variability in IQ in TSC subjects (O’Call-
aghan et al., 2004). Recent work with mouse models of TSC
showed that cognitive deficits can emerge in the absence of
tubers and spontaneous seizures (Ehninger et al., 2008; Goorden
et al., 2007). Studies with a Tsc2+/ mouse model of tuberous
sclerosis demonstrated that TSC-related increases in mTOR
signaling lead to an abnormally low threshold for the late phase
of LTP: conditions that induced only the unstable early phase
of LTP in controls induced instead an abnormally stable potenti-
ation in the mutants (Ehninger et al., 2008). Supposedly, this
abnormal stabilization of LTP results in the inappropriate consol-
idation of error-prone information that interferes with normal
learning and memory processes in TSC.
Strikingly, suppressing mTOR signaling with the FDA-
approved drug rapamycin restored impaired spatial learning
and context discrimination in adult Tsc2+/ mice and reversed
abnormalities in LTP thresholds (Ehninger et al., 2008). Behav-
ioral rescue in adult Tsc2+/ mice occurred after a brief 5 day
treatment with rapamycin, suggesting that the pharmacological
rescue of cognitive deficits was mediated directly through the
inhibition of key biochemical changes in TSC mutant mice.
Biochemical analysis of the mice suggested that these changes
may involve mTOR-dependent increases in neuronal protein
synthesis (Ehninger et al., 2008), which appear to also occur in
other neurogenetic disorders associated with intellectual
disability and autism (Bear et al., 2008; Vanderklish and Edelman,
2005). Unlike patients, mice with heterozygous mutations in the
TSC genes do not exhibit either spontaneous seizures or cortical
tubers (Ehninger et al., 2008; Goorden et al., 2007). Homozygous
astrocyte-specific (Uhlmann et al., 2002) or neuronal-specific
(Ehninger et al., 2008; Meikle et al., 2007) deletions of Tsc1 in
mice, however, result in seizures, neurological impairments,
and high lethality. Remarkably, postnatal treatment with mTOR
inhibitors dramatically reduced seizures, neurological impair-
ments, and lethality in homozygous TSC mutants (Ehninger
et al., 2008; Meikle et al., 2008; Zeng et al., 2008). Despite
improving neurological findings in a homozygous neuronal model
of TSC, mTOR inhibitors did not reverse abnormal neuronal
morphology (orientation of apical dendrites in layer V of the
somatosensory cortex) (Meikle et al., 2008); rapamycin treatment
restored deficient myelination in a homozygous neuronal model
of TSC which may significantly contribute to the improvement
of neurological impairments in these mutant mice (Meikle et al.,956 Neuron 60, December 26, 2008 ª2008 Elsevier Inc.2008). Initiation of rapamycin treatment after seizure onset, in
adolescence, also substantially improved seizures and increased
survival in mice with an astrocyte-specific deletion of the Tsc1
gene (Zeng et al., 2008).
Previous studies with PTEN mutant mice had also documented
surprising recovery of neurological impairment in adult animals
after disease onset (Kwon et al., 2003). PTEN is an upstream
regulator of TSC-mTOR signaling, and mutations in this gene
are linked to Lhermitte-Duclos disease (associated with intellec-
tual disability, ataxia, cerebellar ganglion cell hypertrophy, and
seizures), Cowden syndrome (a multiple hamartoma syndrome),
and autism (Butler et al., 2005; Goffin et al., 2001; Marsh et al.,
1999). Inhibition of mTOR has been found to reverse seizures in
neuronal-specific homozygous PTEN mutant mice, even when
treatment was initiated in adult animals (Kwon et al., 2003). Alto-
gether these studies suggest that disease-related alterations in
TSC-mTOR signaling result in reversible brain dysfunction that
is accessible to pharmacological correction.
Fragile X syndrome (FXS) is another neurodevelopmental
genetic disorder highly associated with intellectual disability
and autism; learning disabilities, ADHD and epilepsy are also
common in this X-linked disorder (Hagerman and Hagerman,
2002). FXS is caused by mutations in the FMR1 gene frequently
involving CGG triplet repeat expansions in the 50 untranslated
region of the gene. This is thought to lead to hypermethylation
and transcriptional silencing of the FMR1 gene. FMR1 encodes
a protein (FMRP) that is thought to be involved in mRNA transport
and translational regulation. According to the ‘‘mGluR theory’’ of
FXS, increased group I mGluR signaling plays a central role in the
pathophysiology of FXS, including associated cognitive dysfunc-
tion (Bear et al., 2004). Recent experimental work provided
compelling support for the role of mGluR signaling in the patho-
genesis of FXS (Dolen et al., 2007). Reducing mGluR signaling
throughout development and adulthood with a heterozygous
mGluR5 germ-line mutation rescued a wide range of phenotypes
in the Fmr1 knockout mouse model of FXS, suggesting that
mGluR signaling plays an important role in FXS.
To determine whether mGluR inhibition is critical in develop-
ment and/or in adults, McBride et al. tested the effect of various
mGluR antagonists on defective courtship behavior, impaired
memory (in a conditioned courtship task), and CNS structural
brain abnormalities in a Drosophila model of FXS (McBride
et al., 2005). Treatment administered exclusively during develop-
ment rescued abnormal courtship behavior, memory impair-
ments, and CNS (mushroom body) neuroanatomical defects in
adult FXS flies. In contrast, treatment of adult FXS flies with
mGluR antagonists partially rescued the abnormal courtship
behavior and the memory impairments without reversing the
structural brain abnormalities. Interestingly, the same treatment
led to impairments in wild-type control flies. These findings
suggest that abnormal mGluR signaling during both develop-
ment and in adulthood contribute to behavioral deficits in FXS
flies. Moreover, rescue of either (developmental or adult) compo-
nent was sufficient to (at least partially) reverse behavioral
impairments in FXS flies. Therefore, it is possible that despite
developmental deficits associated with Fragile X, treatment
with mGluR antagonists in adulthood may significantly improve
behavioral and cognitive function.
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genes on chromosome 15q11-13 or mutations in the UBE3A
gene (Kishino et al., 1997; Knoll et al., 1989). Individuals affected
by Angelman syndrome typically appear normal at birth but show
clear developmental delays by 6–12 months. Associated neuro-
logical, behavioral, and cognitive symptoms frequently include
intellectual disability, seizures, movement disorders, language
impairments, hyperactivity, and learning disabilities (Williams
et al., 2006). A mouse model of Angelman syndrome that carries
a mutation in the maternally inherited Ube3a gene (Ube3ap+/m–)
recapitulates features of the human disorder, including motor
impairments, learning deficits, and seizures (Jiang et al., 1998).
Ube3ap+/m– mice show increased inhibitory autophosphorylation
of aCaMKII and deficient hippocampal long-term potentiation
(Weeber et al., 2003). To test whether increased inhibitory
autophosphorylation of aCaMKII accounts for cognitive and
neurological symptoms of Ube3ap+/m– mice, these mice were
crossed to mutants heterozygous for a mutation that prevents
inhibitory autophosphorylation of aCaMKII (aCaMKII-T305V/
T306A) (van Woerden et al., 2007). Strikingly, a range of
Ube3ap+/m– phenotypes (audiogenic seizures, motor coordina-
tion deficits, hippocampus-dependent learning deficits, defi-
cient hippocampal long-term potentiation) was rescued
by a heterozygous aCaMKII-T305V/T306A mutation. These
findings suggest that Angelman syndrome-related neurological
and cognitive phenotypes may result from decreased aCaMKII
activity due to increased inhibitory autophosphorylation.
aCaMKII expression is largely restricted to the postnatal brain
(Colbran et al., 1989), implicating disturbed postnatal develop-
ment and/or adult function in the pathophysiology of Angelman
syndrome-related neurological and neurocognitive symptoms.
Rett syndrome (Rett, 1966) is another X-linked developmental
genetic disorder associated with intellectual disability, autistic
features (impaired reciprocal social interaction, language and
communication deficits, stereotyped behaviors) and motor
symptoms (delay or absence of walking, ataxia, respiratory
dysfunction, hypotonia, dystonia, chorea, spasticity). Affected
girls are initially asymptomatic and neurological abnormalities
start to emerge by the age of 6–18 months. Rett syndrome is
caused by mutations in the X-chromosomal gene MECP2 (Amir
et al., 1999), which encodes the transcriptional regulator
MeCP2. Mecp2 expression in the brain is restricted to cells of the
neuronal lineage and increases with neuronal maturation (Kishi
and Macklis, 2004). Several mouse models of Rett syndrome
have been engineered by deleting murine Mecp2 (Chen et al.,
2001; Guy et al., 2001; Shahbazian et al., 2002). Mecp2 null
male mice show progressive neurological disease (gait abnor-
malities, hindlimb clasping, respiratory dysfunction) and high
mortality. Female mutant mice also display progressive neuro-
logical impairments, which eventually stabilize and by-and-large
do not interfere with survival. Mecp2 mutant mice have lower
brain volumes, accompanied by normal neuron numbers but
decreased neuronal arborization.
Recently, a loxP genetic strategy was used to restore Mecp2
levels in Mecp2 mutant mice at various ages (Guy et al., 2007):
the authors first silenced Mecp2 by insertion of a lox-STOP
cassette. Later, at specific time points, Mecp2 expression was
restored by inducible activation of Cre recombinase; the recom-binase excised the lox-STOP cassette, thereby allowing expres-
sion of the Mecp2 gene. Gradually restoring Mecp2 expression
after the onset of neurological symptoms—that include hindlimb
clasping, inertia, irregular breathing, gait, and tremor—reversed
these impairments and improved survival in male Mecp2 mutant
mice. Accordingly, restoring Mecp2 expression in mature female
mutant mice, after onset of neurological disease, reversed func-
tion to wild-type levels and restored proper levels of neuronal
plasticity. These remarkable results demonstrate that deficits
caused by Mecp2 loss in development do not result in irrevers-
ible deficits. Instead, these data demonstrate that restoring
function in adults can reverse at least some of the deficits caused
by loss of gene function during development.
Interestingly, a lower excitation-to-inhibition ratio was found in
the neocortex ofMecp2mutant mice (Dani et al., 2005). Fragile X
mice showed reduced excitatory drive of inhibitory neurons and
thus an increased excitation to inhibition ratio (Gibson et al.,
2008). As reviewed above, both NF1 and Down’s syndrome
mouse models were found to have higher levels of inhibition
but normal excitation (see above) (Costa et al., 2002; Kleschev-
nikov et al., 2004). The analyses of these four models suggest
that a change in the ratio of excitation to inhibition is an important
feature of neurodevelopmental disorders (Rubenstein and Mer-
zenich, 2003).
Taken together, the studies summarized above suggest that
cognitive disability in classic ‘‘neurodevelopmental’’ disorders
may be reversible in adults, even when developmental neuroan-
atomical abnormalities are not reversed. Thus, these studies
demonstrate that, for at least some of these disorders, loss of
gene function specifically in adults makes a sizeable contribution
to the resulting pathology and that treating this facet of the
disorder, in animal models, can result in dramatic improvements.
A cautionary note is however in order: we do not know whether
the rescues described in this review will be the norm for neuro-
developmental disorders or whether these results in mice will
be mirrored by similar findings in humans. Indeed, we mentioned
examples where normal gene function in adults does not reverse
developmental deficits (Gross et al., 2002; Li et al., 2007).
Plasticity of the Adult Brain and the Treatment
of Neurodevelopmental Disorders
An interesting possibility is that adult rescue of genetic defects,
such as those mentioned above, alleviate or correct develop-
mental phenotypes by tapping into adult mechanisms of cellular,
structural, and behavioral plasticity. A large number of studies
have shown that the developing brain is endowed with high
levels of plasticity that are vital for shaping its structure and func-
tion. The classical view has been that plasticity is restricted to a
defined window in time known as the critical period (Hubel and
Wiesel, 1970). For example, the critical period for ocular domi-
nance plasticity occurs from 19 to 32 days of age in the mouse
(Gordon and Stryker, 1996). Critical periods are usually defined
as times in development when changes in sensory input can alter
the structure and function of the brain, but they may also exist
outside of primary sensory areas. For example, the acquisition
of specific cognitive skills, such as language, also appears to
be constrained by specific ontological windows in humans
(Lenneberg, 1967).Neuron 60, December 26, 2008 ª2008 Elsevier Inc. 957
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developmental plasticity, including structural changes in spines
(Trachtenberg et al., 2002), axons (Florence et al., 1998), and
dendrites (Tailby et al., 2005). Plasticity can occur at high levels
in the somatosensory cortex into adulthood (Clark et al., 1988;
Fox, 1992; Merzenich et al., 1984; reviewed in Buonomano and
Merzenich, 1998) and plasticity in the visual cortex can also occur
beyond the classical critical period (Daw et al., 1992; Sawtell
et al., 2003). One possibility for therapies therefore lies in using
the inherent natural plasticity of adult brain for restoration of
function.
Another possibility is to tap into the plasticity mechanisms
present during developmental critical periods. Even though plas-
ticity is present in adult animals, it does not appear to have the
same set of mechanisms that are present in developing animals.
For example, spine motility decreases beyond the critical period
(Holtmaat et al., 2005), thalamocortical axon plasticity and thala-
mocortical LTP are reduced or eliminated, respectively (Crair
and Malenka, 1995; Hubel and Wiesel, 1977), silent synapses
are eliminated (Isaac et al., 1997; Rumpel et al., 2004), and
presynaptic NMDA receptors, which are important for a develop-
mental form of synaptic depression, are lost (Corlew et al., 2007).
The loss or reduction of these factors (and most likely others yet
to be discovered) means that adult plasticity is slower to take
effect and lacks some of the features of developmental plasticity.
It was therefore a source of great interest and excitement
when it was discovered that the critical period could be delayed
and manipulated by altering levels of cortical inhibition (Hensch
et al., 1998), and plasticity resembling that in the critical period
could be reinstated in adult animals by degradation of compo-
nents of the extracellular matrix surrounding the inhibitory cells
with the enzyme chondroitinase (Pizzorusso et al., 2002). Since
that report, other treatments, such as administering the antide-
pressant fluoxetin (a serotonine/norepinephrine reuptake inhib-
itor; Maya Vetencourt et al., 2008) and exposure to an enriched
environment, have also been found to increase sensory plasticity
in adult animals (Sale et al., 2007). These findings suggest that
the adult brain could retain the potential for some features of
developmental plasticity.
Inhibition is a possible common link between factors that have
so far been found to increase adult plasticity. The critical period
can be delayed in the visual cortex if the function of the inhibitory
system is attenuated and reinstated by increasing inhibition
(Hensch et al., 1998). Interestingly, the shift toward higher inhibi-
tion observed in several models of neurodevelopmental disor-
ders reviewed here raises the possibility for premature closure
of critical periods in these mutant mice, a mechanism that could
contribute to their deficits. It is possible that high levels of plas-
ticity, characteristic of critical periods, are actively suppressed in
adults by mechanisms such as increased levels of inhibition
(Spolidoro et al., 2008). Accordingly, strategies that decrease
inhibition may reactivate ‘‘developmental’’ levels of plasticity
and reopen developmental windows in the adult brain.
Conclusions
Altogether the findings reviewed here mark a paradigmatic
change in the way we understand and envision treating neurode-
velopmental disorders. They show that reversing the underlying958 Neuron 60, December 26, 2008 ª2008 Elsevier Inc.molecular deficits of these disorders can result in dramatic
improvements in cognitive function even if treatments are started
in adulthood. These findings also highlight the surprising poten-
tial for plasticity in the adult brain, and they raise the possibility
that adult rescue of phenotypes associated with neurodevelop-
mental disorders may take advantage of these mechanisms.
Additionally, these results may also have implications for
treating other disorders, such as brain injury, stroke, addiction,
etc. For example, prolonged substance abuse leads to stable
molecular, cellular, structural, and behavioral changes that
present a formidable problem for recovering patients (Volkow
and Li, 2005). The results reviewed here suggest that correcting
the maladaptive biochemical states brought about by these
disorders (e.g, addiction, brain injury, etc.) may allow the brain
to recover, even when key neuroanatomical changes associated
with pathology are not reversed. In addition to correcting disrup-
ted molecular processes, it is possible that manipulations that
reopen highly plastic developmental states may facilitate
recovery from neurodevelopmental disorders, addiction, or any
other disorder that disrupts the structure and function of the
brain. Altogether the findings reviewed here raise the possibility
that adult treatments could one day help the many millions of
people affected with neurodevelopmental disorders. They also
highlight the importance and urgency of understanding the
absolutely fascinating ability of the adult brain to reinvent itself.
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